PRX-00023, a selective serotonin 1A receptor agonist, reduces ultrasonic vocalizations in infant rats bred for high infantile anxiety.
To address the development of early anxiety disorders across the lifespan, the High USV line of rats was bred based on rates of infant ultrasonic vocalization in the 40-50 kHz range of predominant frequencies (USV) to maternal separation at postnatal day (P) 10. In this study, rates of USV in High line infants (pups: Postnatal Day 11+/-1) were compared to those of randomly-bred controls in response to EPIX compound PRX-00023, a unique serotonin (5-HT) agonist, acting exclusively at the 5-HT1A receptor, or buspirone, a nonspecific 5HT1A agonist. After testing, pups were examined for sedation and other drug-related effects. The results indicated that all doses of buspirone reduced USV rates in isolation, consistent with other reports. PRX-00023 significantly reduced USV rates at the lowest doses (0.01-0.05 mg/kg). None of the PRX-00023 doses produced sedation, whereas all but the lowest dose of buspirone (0.1 mg/kg) produced sedation effects. The results suggest that this compound alleviates infantile anxiety-like behavior with great specificity in rats bred for high anxiety/depressive phenotypes by selectively targeting 5-HT1A receptors, possibly by both pre- and post-synaptic mechanisms.
Brunelli
Susan A
SA
Division of Developmental Neuroscience, New York State Psychiatric Institute, 1051 Riverside Drive, New York, NY 10032, USA. sab9@columbia.edu
Aviles
Jessica A
JA
Gannon
Kimberly S
KS
Branscomb
Aron
A
Shacham
Sharon
S
D000375:Aging; D000818:Animals; D014151:Anti-Anxiety Agents / Q000008:administration & dosage / Q000494:pharmacology*; D001007:Anxiety / Q000188:drug therapy* / Q000235:genetics; D001008:Anxiety Disorders / Q000188:drug therapy; D001010:Anxiety, Separation / Q000188:drug therapy; D001259:Ataxia / Q000139:chemically induced; D001831:Body Temperature / Q000187:drug effects; D002065:Buspirone / Q000008:administration & dosage / Q000494:pharmacology*; D004195:Disease Models, Animal; D004305:Dose-Response Relationship, Drug; D004609:Eliminative Behavior, Animal / Q000187:drug effects; D005260:Female; D006120:Grooming / Q000187:drug effects; D006824:Hybridization, Genetic; D008297:Male; D009068:Movement / Q000187:drug effects; D010879:Piperazines / Q000008:administration & dosage / Q000494:pharmacology*; D051381:Rats; D011930:Reaction Time / Q000187:drug effects; D058825:Serotonin 5-HT1 Receptor Agonists; D012727:Sex Characteristics; D012934:Social Isolation; D013449:Sulfonamides / Q000008:administration & dosage / Q000494:pharmacology*; D014465:Ultrasonics; D014828:Vocalization, Animal / Q000187:drug effects*
D014151:Anti-Anxiety Agents; D010879:Piperazines; D058825:Serotonin 5-HT1 Receptor Agonists; D013449:Sulfonamides; C511631:naluzotan; D002065:Buspirone